Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals (CSE:AGN) welcomes Dr. Mark Williams to the board

John Ballem  September 22, 2021

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study

GlobeNewswire September 22, 2021

Algernon Pharmaceuticals Announces the Appointment of Dr. Mark Williams to the Board of Directors

GlobeNewswire September 22, 2021

Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.

GlobeNewswire September 20, 2021

Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company's DMT Program at the International Microdose DMT Conference

GlobeNewswire September 9, 2021

Algernon Pharmaceuticals (CSE:AGN) welcomes Harry Bloomfield, QC. as a board director and chairman

John Ballem  September 9, 2021

Algernon Pharmaceuticals Announces Appointment of Harry Bloomfield, QC. as a New Board Director and Chairman

GlobeNewswire September 9, 2021

Algernon Pharmaceuticals Confirms DMT Increases Neuron Growth

Trevor Abes  September 7, 2021

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

GlobeNewswire September 7, 2021

Leading DMT Companies to Take Stage at Molecular Masterclass: DMT Conference

Newsfile September 1, 2021

Top 5 Stories of the Week: EV Battery Tech (CSE:ACDC), Bluesky Digital Assets (CSE:BTC), Algernon Pharmaceuticals (CSE:AGN), E79 Resources (CSE:ESNR), and Naturally Splendid (TSXV:NSP)

Trevor Abes  August 13, 2021

Algernon Announces Ifenprodil Research Program & Appoints Dr. William North as Lead Consultant

John Ballem  August 11, 2021

Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant

GlobeNewswire August 11, 2021

Algernon Pharmaceuticals Announces Licensing Agreement with Dartmouth College

John Ballem  August 9, 2021

Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College

GlobeNewswire August 9, 2021

Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

Newsfile July 27, 2021

Algernon Pharmaceuticals (CSE:AGN) reaches 70 per cent enrollment target for its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Brieanna McCutcheon  July 7, 2021

Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

GlobeNewswire July 7, 2021

Algernon Pharmaceuticals (CSE:AGN) will not be advancing its clinical trial of Ifenprodil for COVID-19

Jocelyn Aspa July 6, 2021

Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19

GlobeNewswire July 6, 2021